Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

605
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
605
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

613
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
613
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

657
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
657
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

912
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
912
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

1.5K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

725
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
725

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Postoperative Pain Outcomes and Satisfaction in Preschool Versus School-Age Children: A Prospective Multicenter Observational Study.

Cureus·2026
Same author

On the Coexistence of Monitoring and Dampening of Pain Perception During the Fight-or-Flight Response.

Cureus·2026
Same author

Combination of the BK-Channel Antagonist ENA-001 and Naloxone Is More Effective Than Either Agent Alone in Reversing Fentanyl-Induced Respiratory Suppression in Rats.

Cureus·2026
Same author

A Pain Memory "Trace": Cumulative Pain Perception and Damping During Fight-or-Flight Response Modeled with a Lotka-Volterra-Style Coupled Feedback Control Loop System.

Journal of pain research·2026
Same author

Defining, Evaluating, and Managing Postoperative Respiratory Depression: An e-Delphi Study.

Cureus·2026
Same author

A Pilot Convenience Survey of Clinicians' Perception of the Desirability of a Lower Dose Option of an Opioid Analgesic: Hydrocodone as an Example.

Cureus·2026

Related Experiment Video

Updated: Mar 24, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

3.5K

Evolution to low-dose NSAID therapy.

Joseph V Pergolizzi1,2, Robert B Raffa3, Srinivas Nalamachu4

  • 1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Pain Management
|March 17, 2016
PubMed
Summary
This summary is machine-generated.

Non-steroidal anti-inflammatory drugs (NSAIDs) carry risks of adverse effects. Low-dose NSAID formulations aim to reduce these risks by lowering systemic exposure, warranting a review of their use.

Keywords:
NSAIDacute painadverse effectschronic pain

More Related Videos

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.8K
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
12:44

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs

Published on: January 27, 2023

4.6K

Related Experiment Videos

Last Updated: Mar 24, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

3.5K
Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish
07:50

Facilitating Drug Discovery: An Automated High-content Inflammation Assay in Zebrafish

Published on: July 16, 2012

14.8K
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
12:44

Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs

Published on: January 27, 2023

4.6K

Area of Science:

  • Pharmacology
  • Drug Safety
  • Gastroenterology

Background:

  • Non-steroidal anti-inflammatory drugs (NSAIDs) are associated with gastrointestinal, cardiovascular, and renal adverse effects (AEs).
  • COX isozyme selectivity (COX-1/COX-2) has been used to predict AE likelihood, but this measure is imperfect and has not guaranteed superior safety.
  • Current guidelines advocate for using NSAIDs at the lowest effective dose for the shortest duration.

Purpose of the Study:

  • To review the rationale and application of low-dose NSAID formulations.
  • To assess the potential benefits of reduced systemic exposure for mitigating NSAID-related AEs.

Main Methods:

  • Review of existing literature on NSAID pharmacology and safety.
  • Analysis of the concept of COX isozyme selectivity.
  • Evaluation of the development and proposed benefits of low-dose NSAID formulations.

Main Results:

  • NSAID selectivity for COX isozymes does not consistently predict safety.
  • Low-dose formulations are a response to guidelines recommending minimal NSAID exposure.
  • Reduced systemic exposure from low-dose NSAIDs may decrease AE frequency or severity.

Conclusions:

  • The development of low-dose NSAID formulations addresses the need for safer NSAID use.
  • Further evaluation of the need, rationale, and application of these formulations is timely.
  • Optimizing NSAID therapy may involve strategies to reduce overall patient exposure.